BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly Acquires Verve Therapeutics in $1.3 Billion Gene-Editing Deal
Eli Lilly Acquires Verve Therapeutics in $1.3 Billion Gene-Editing Deal
14
1
Eli Lilly (LLY) is making a strategic leap into the gene-editing arena with its $1.3 billion acquisition of Verve Therapeutics (VERV). The deal, priced at $10.50 per share plus a $3 contingent value right, sent VERV stock soaring 81.5% on June 17, while LLY shares dipped 2%.
The partnership builds on existing collaborations in cardiovascular treatments, with Verve's VERVE-102 showing promise in clinical trials—demonstrating a 53% reduction in cholesterol levels without safety concerns. Gene editing, increasingly augmented by AI advancements, represents a transformative frontier in biopharma.
By:
Previous
Federal Reserve Holds Rates Steady Amid Growing Stagflation Concerns
Next
Texas Instruments (TXN) Stock Rises on $60B U.S. Manufacturing Expansion Plan
